Skip to main content
. Author manuscript; available in PMC: 2024 Jul 30.
Published in final edited form as: Vaccine. 2024 May 3;42(16):3555–3563. doi: 10.1016/j.vaccine.2024.04.061

Table 3.

Serotype specific vaccine effectiveness against IPD for ≥ 3 doses of PCV13, May 1, 2010 - December 31, 2019.

Serotype Exposure1 Serotype specific Cases Non-PCV13-type Controls Unadjusted Adjusted2
N (%) N (%) VE (95 % CI) VE (95 % CI)
Serotype 19A
No doses of PCV13 80 (67.2) 85 (12.4) ref. ref.
≥3 doses PCV13 39 (32.8) 600 (87.6) 93.1 (89.3,95.6) 86.8 (73.7,93.3)
Serotype 3
No doses of PCV13 18 (33.3) 85 (12.4) ref. ref.
≥3 doses PCV13 36 (66.7) 600 (87.6) 71.7 (48.3,84.7) 50.2 (−28.4,80.5)
Serotype 7F
No doses of PCV13 24 (96.0) 85 (12.4) ref. ref.
≥3 doses PCV13 1 (4.0) 600 (87.6) 99.4 (95.6,99.9) 94.5 (13.5,99.6)
Serotype 19F
No doses of PCV 8 (25.0) 15 (2.4) ref. ref.
≥3 doses PCV13 24 (75.0) 600 (97.6) 92.5 (80.8,97.1) 93.8 (69.8,98.8)

Abbreviations: VE = Vaccine Effectiveness; PCV = pneumococcal conjugate vaccine; PCV13- 13-valent pneumococcal conjugate vaccine; CI = confidence interval; ref. = reference level.

1

For the assessment of Serotype 19A, 3 and 7F VE, participants who received either 7-valent pneumococcal conjugate vaccine (PCV7) or no doses of any pneumococcal vaccination were included in the reference group (No doses of PCV13). For the assessment of Serotype 19F VE, participants were included in the reference group if they received no doses of any PCV products. Persons who received PCV7 only were excluded from this analysis.

2

Logistic regression model adjusted for age (categorical), race/ethnicity (combined variable), sex, state, calendar year, immunocompromising conditions, chronic conditions or asthma.